首页> 美国卫生研究院文献>California Medicine >Pediatric Renal Transplantation
【2h】

Pediatric Renal Transplantation

机译:小儿肾移植

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thirty-one children received 38 kidney transplants from 22 live and 16 cadaver donors. Among the 31 patients, 25 received one transplant each, 5 received two transplants each and 1 received three transplants. Peritoneal or hemodialysis (or both) was carried out in 22 patients, with an average dialytic maintenance of 12 weeks before transplantation. Posttransplant immunosuppressive therapy included prednisone and azathioprine. Antilymphocyte globulin was administered to 33 recipients as adjunctive immunosuppressive therapy.At present, 23 patients have functioning allografts, 3 are on hemodialysis and 5 are dead. Of 22 live kidney transplants, 18 are presently functioning two months to 14 years after transplantation with an average of 36 months. Of 16 cadaver kidney transplants, 5 are presently functioning 9 to 57 months after transplantation with an average of 32 months. Actuarial live donor allograft survival for one year was 76 percent, for two years was 66 percent and for three years was 64 percent. Cadaver allograft survival was 50 percent, 40 percent and 40 percent, respectively.Complications were urologic and infection related. Of nine recipients with sustained hypertension, in six the condition was due to chronic rejection, while in one it was due to recurrence of the original disease in the allograft. Linear growth was measured in 15 children who were less than 14 years of age at the time of transplantation and in whom allografts survived more than one year. Maximum average linear growth velocity occurred during the first year after transplantation. Our experience indicates pediatric renal transplantation can be successfully used in the treatment of terminal renal failure.
机译:31名儿童从22位活人和16位尸体捐赠者那里接受了38例肾脏移植。在这31例患者中,有25例接受了一次移植,5例接受了两次移植,1例接受了3次移植。在22例患者中进行了腹膜或血液透析(或两者),平均透析维持时间为移植前12周。移植后免疫抑制治疗包括泼尼松和硫唑嘌呤。 33例接受抗淋巴细胞球蛋白作为辅助免疫抑制疗法的患者。目前,有23例具有同种异体功能的患者,其中3例接受血液透析,5例死亡。在22例活体肾脏移植中,目前有18例在移植后2个月至14年内起作用,平均36个月。在16例尸体肾脏移植中,目前有5例在移植后9到57个月起作用,平均32个月。精算活体供体同种异体移植的存活率为76%,两年为66%,三年为64%。尸体同种异体移植存活率分别为50%,40%和40%。并发症与泌尿外科和感染相关。在9位持续高血压患者中,有6位是由于慢性排斥反应引起的,而在1位是由于同种异体移植原发病的复发。在移植时未满14岁且同种异体移植存活超过一年的15名儿童中测量了线性生长。最大平均线性生长速度发生在移植后的第一年。我们的经验表明,小儿肾脏移植可成功用于治疗晚期肾衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号